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The Human Papillomavirus E6 oncoproteins have the capacity to target several of their cellular
interacting partners for proteasome mediated degradation, and recent proteomic analyses suggest a
close involvement of E6 with the cellular proteasome machinery. In this study we have performed an
extensive analysis of the capacity of different E6 oncoproteins to interact with speciﬁc proteasome
components. We demonstrate that multiple subunits of the proteasome can be bound by different HPV
E6 oncoproteins. Furthermore, whilst most of these interactions appear independent of the E6AP
ubiquitin ligase, the association of E6 with the major ubiquitin-accepting proteasome subunit, S5a, does
require the presence of E6AP. One consequence of the interaction between E6/E6AP and S5a is enhanced
ubiquitination of this proteasome subunit. These results suggest a complex interplay between E6 and the
proteasome, only some aspects of which are dependent upon the E6AP ubiquitin ligase.
& 2013 The Authors. Published by Elsevier Inc.
Introduction
Human Papillomaviruses (HPVs) are the causative agents of
cervical cancer. They are also responsible for a large number of
other anogenital cancers, plus an increasing number of head and
neck cancers (Bouvard et al., 2009). Currently over 150 different
HPV types have been described, but only a small subset of these,
the so-called high-risk types are cancer-causing and these are
exempliﬁed by types HPV-16 and HPV-18 (Doorbar et al., 2012).
The HPV E6 and E7 oncoproteins are essential for the ability of the
virus to induce cervical cancer. They cooperate in the immortalisa-
tion of primary human keratinocytes (Hawley-Nelson et al., 1989;
Barbosa and Schlegel, 1989), the natural target cell of the virus
in vivo, and also cooperate in the induction of cervical cancer in
transgenic animals (Riley et al., 2003). Furthermore, both E6 and
E7 are retained and expressed in the tumours many years after the
initial immortalising events, suggesting a continuing role in
tumour development and maintenance (Smotkin and Wettstein,
1986; Androphy et al., 1987; Banks, et al., 1987). Indeed a large
number of studies have shown that inhibition of their expression
or function has deleterious effects upon continued tumour cell
proliferation, resulting in the induction of apoptotic and senes-
cence phenotypes (Yoshinouchi et al., 2003; Butz et al., 2003).
Thus both of these viral oncoproteins are prime targets for
therapeutic intervention in HPV-associated diseases.
The high-risk HPV E6 and E7 oncoproteins function by perturbing
key elements of cellular homoeostasis (Doorbar et al., 2012). HPV E7
is primarily responsible for inducing an environment favourable for
viral DNA replication. This occurs through perturbation of key cell
cycle regulators such as the pRb family of tumour suppressors and
the cyclin dependent kinase inhibitors (Dyson et al., 1989; Funk et al.,
1997). HPV E6 on the other hand is largely responsible for blocking
the cell's normal pro-apoptotic responses that are induced as a result
of E7 activity. This is achieved in part through blocking the normal
pro-apoptotic activities of p53 and Bak (Kessis et al., 1993; Thomas
and Banks, 1998). Intriguing features of both E6 and E7 are their
abilities to direct many of their cellular substrates for proteasome-
mediated degradation (Banks et al., 2003). In the case of E7, this is
seen for pRb, p130 and p107, and in the case of pRb, involves
recruitment of the cellular cullin-2 ubiquitin ligase complex to induce
poly-ubiquitination of the substrate, which is then directed for
subsequent degradation at the 26S proteasome (Gonzalez et al.,
2001; Huh et al., 2007). In the case of E6, major degradation targets
include p53 (Scheffner et al., 1990) and a number of different PDZ
domain-containing proteins (Gardiol et al., 1999; Nakagawa and
Huibregtse, 2000). For many of these substrates, this degradatory
activity relies upon the ability of E6 to recruit the cellular ubiquitin
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ligase E6AP to the E6-substrate complex, which in turn results in
substrate poly-ubiquitination and degradation at the proteasome
(Scheffner et al., 1993). Thus, whereas much is known about the
ubiquitin ligases that are recruited by the viral oncoproteins to direct
their substrates for degradation, much less is known about the
capacity of these oncoproteins to associate directly with the protea-
some itself.
The 26S proteasome is a multi-subunit macromolecular
machine, composed of multiple protein components, which cap-
tures ubiquitin-conjugated proteins via the 19S regulatory cap that
sits above the catalytic 20S proteolytic core (Kish-Tier and Hill,
2013). Bound to this is the S5a subunit, which interacts with
polyubiquitinated chains and is believed to either tether or direct
such polyubiquitinated proteins directly to the proteasome for
subsequent degradation (Wang et al., 2005; Isasa et al., 2010).
Interestingly, signiﬁcant amounts of S5a protein are not directly
bound to the proteasome complex at any given time, suggesting
that it may also have additional regulatory roles within the cell. In
the case of HPV, recent proteomic analyses have identiﬁed multi-
ple proteasome subunits, including S5a, as potential interacting
partners of the HPV E6 oncoproteins (Tomaić et al., 2011;
Rozenblatt-Rosen et al., 2012) and its associated ubiquitin ligase
E6AP (Martinez-Noel et al., 2012), with previous studies also
showing that E6AP could directly ubiquitinate the S5a subunit
(Uchiki et al., 2009). Whether individual components of the
proteasome can be bound by E6 and whether this simply reﬂects
an indirect association that is mediated via E6AP, however,
remains to be determined. We were therefore interested in
investigating whether the HPV E6 oncoproteins can directly
interact with the isolated ubiquitin subunits and, furthermore, in
determining the potential role for E6AP in this recognition process.
We now show that multiple subunits can be directly bound by E6,
but that the gatekeeper subunit, S5a, is bound and polyubiquiti-
nated by E6 in an E6AP-dependent manner.
Results
HPV E6 interacts with multiple proteasome subunits
Recent proteomic analyses have identiﬁed multiple proteasome
subunits as potential interacting partners of the HPV E6 oncopro-
teins and of the associated E6AP ubiquitin ligase (Tomaić et al.,
2011; Rozenblatt-Rosen et al., 2012; Martinez-Noel et al., 2012).
This raises the question of which, if any, of these proteasome
subunits is bound directly by the HPV E6 oncoproteins. To
investigate this, we ﬁrst performed a series of GST pull-down
assays using either full length GST.18E6 or the alternatively spliced
GST.18E6n, which lacks most of the carboxy terminal half of the
protein. These were incubated with a large panel of [35S]-methio-
nine radiolabeled proteasome subunits that were translated in a
wheat germ system (WGE), so as to avoid any possible contamina-
tion with E6AP. The results obtained are shown in Fig. 1, where it
can be seen that both the full length HPV-18 E6 (Fig. 1A) and the
alternatively spliced HPV-18 E6n (Fig. 1B) are capable of interacting
with multiple proteasome subunits, with particularly strong asso-
ciations seen between E6 and the S4 and S8 subunits. Interestingly,
there is remarkable similarity between the E6n and the full-length
HPV-18 E6 oncoprotein, both in terms of the pattern of subunits
recognised and in the relative strengths of interaction. This
indicates that the capacity of HPV-18 E6 to interact with the
individual proteasome subunits is contained within sequences
lying primarily within the N-terminal half of the protein. It is also
noteworthy that whilst the S5a subunit was identiﬁed in the
proteomic analyses as a potential interacting partner of HPV-18 E6,
this subunit does not seem to be bound by E6 under these in vitro
conditions.
Having found that HPV-18 E6 has the potential to interact with
multiple proteasome subunits we wanted to determine how the
strength of this interaction compared with some of E6's strongest
bound partners, the PDZ domain containing substrates Dlg and
Scribble. To do this GST pull down assays were performed using
GST.18E6 and in vitro translated [35S]-methionine radiolabeled Dlg,
Scribble and for comparison, the S4 subunit. The results in Fig. 1C
show a very strong association between E6 and the PDZ domain
containing substrates (approximately 46% of input bound) in agree-
ment with previous studies (Gardiol et al., 1999; Nakagawa and
Huibregtse, 2000), with a somewhat weaker but nonetheless highly
signiﬁcant interaction (approximately 12% of input bound) with the
S4 subunit.
We next proceeded to compare the relative abilities of the low
risk HPV-11 E6 and the high risk HPV-16 E6 to interact with
selected proteasome subunits. In this case we used puriﬁed GST
fusion proteins of the S2 and S4 subunits, as examples of weak and
strong interacting partners of HPV-18 E6, and performed interac-
tion assays with [35S]-cysteine radiolabeled E6 proteins, which
were translated in the wheat germ system. The results in Fig. 2
demonstrate that HPV-16 E6 interacts most strongly with the
proteasome subunits, and with a very similar afﬁnity for both S2
and S4. HPV-18 E6, recognises both subunits, but again binds to S4
somewhat more strongly than it does to the S2 subunit. In
contrast, HPV-11 E6 can also interact with both proteasome
subunits, but in this case binds S2 and S4 to a similar weak degree.
These results demonstrate that the capacity of the HPV E6
oncoproteins to interact with individual subunits of the protea-
some is conserved across different HPV types, but that there are
signiﬁcant differences in the levels to which different E6 oncopro-
teins can recognise speciﬁc proteasome subunits.
The above assays were all performed in the absence of E6AP,
however we wanted to determine if the pattern of proteasome
subunits recognised by HPV-18 E6 might differ if E6AP was
present. To do this we repeated the interaction assays using a
panel of different GST fusion proteins of the proteasome subunits,
incubated with [35S]-cysteine radiolabeled E6 that had been
in vitro translated in rabbit reticulocyte lysates (RRL). The results
in Fig. 3A generally show a pattern of proteasome subunit
recognition by the HPV-18 E6 protein that is very similar to that
seen using the wheat germ expression system. However, there is a
marked increase in the capacity of HPV-18 E6 to interact with the
S5a subunit. Interestingly, when this interaction assay was done
with E6n, there was still no interaction with the S5a subunit (data
not shown). This suggests that the capacity of E6 to recognises the
S5a subunit of the proteasome requires the full length E6 protein
and furthermore, is most likely indirect and potentially mediated
via the E6AP ubiquitin ligase.
To investigate this possibility further, we transfected HA-tagged
HPV-18 E6 into 293 cells where E6AP expression was either wild
type or stably knocked down following transfectionwith an shRNA
targeting vector (Fig. 3B iii). After 24 h the cells were extracted and
interaction assays performed using a GST fusion protein of the S5a
subunit. Bound E6 was then detected by anti-HA Western blotting.
The results in Fig. 3B demonstrate a very efﬁcient pull-down of
HPV-18 E6 from the transfected 293 cells with the GST S5a fusion
protein, but only when E6AP is present. These results conﬁrm that
HPV-18 E6 can recognise the S5a proteasome subunit but that this
is dependent upon the presence of E6AP.
HPV E6 induces polyubiquitination of S5a.
The S5a subunit is one of the proteasome's major acceptors of
polyubiquitin chains and is potentially a critical controlling factor
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Fig. 1. HPV-18 E6 can interact with multiple proteasome subunits. The indicated proteasome subunits were in vitro translated and radiolabelled using wheat germ extracts
(WGE) and then incubated with puriﬁed GST, GST.18E6 (Panel A) or GST.18E6* (Panel B) as indicated. After extensive washing the bound proteins were detected by SDS-PAGE
and autoradiography. The upper panels show 20% of the in vitro translated protein inputs used in the pull down assays. The two lower panels show the autoradiogram and
the Coomassie stain of the gel conﬁrming equal levels of protein loading. For comparison interaction (Panel C) assays were performed with puriﬁed GST or GST.18E6 with
in vitro translated and radiolabelled S4 subunit, Dlg and Scribble (hScrib). The upper panel shows the amount of in vitro translated protein bound by the GST and GST.18E6,
with the numbers showing the percentage of input protein bound and the lower panel showing the Coomassie stain of the gel conﬁrming equal levels of protein loading.
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in regulating protein degradation at the proteasome (Elangovan
et al., 2009; Wang et al., 2005; Isasa et al., 2010). The above results
suggest that E6 can potentially recognise multiple proteasome
subunits, but that recognition of the S5a subunit is dependent
upon E6AP. Since the E6-E6AP complex functions as unique
ubiquitin ligase, where E6 provides novel substrate speciﬁcity
for the E6AP ubiqutin ligase, we next wanted to determine
whether E6 might have any inﬂuence on S5a stability. To do this,
the HPV-16 and HPV-18 E6 proteins, together with the S5a
subunit, were in vitro translated and radiolabeled in rabbit
reticulocyte lysate. The translates were then mixed and incubated
together for different periods of time, and the pattern of S5a
expression ascertained following SDS-PAGE and autoradiography.
The results obtained are shown in Fig. 4A. As can be seen, there is
very little change in the pattern of S5a expression alone over the
period of the assay. However, in the presence of HPV-16 E6 there is
a slight reduction in the levels of S5a protein, with a correspond-
ing dramatic increase in the appearance of higher molecular
weight slower migrating forms of the protein. This laddering of
S5a is also seen in the presence of HPV-18 E6, but is much weaker.
The appearance of the slower migrating forms of the S5a
protein is apparent within 30–60 min of incubation with HPV-16
E6, and we wanted to determine how quickly these modiﬁcations
could be induced. To do this the assay was repeated, but the
pattern of expression was monitored from 5 mins onwards. As can
be seen from Fig. 4B, HPV-16 E6 induces a readily detectable
change in the pattern of S5a protein expression after 15–30 min of
incubation, with higher molecular weight forms appearing by
1–3 h. By 5 h these higher molecular weight forms of S5a begin
to disappear. These results indicate that the HPV-16 E6 induced
modiﬁcation to S5a is quite rapid, whilst E6-induced degradation
of S5a is only very weak when compared to the rate of degradation
observed with the p53 control.
The S5a proteasome subunit is a major acceptor of ubiquitin
chains, and the pattern of laddering seen in the in vitro assays is
very reminiscent of ubiquitination. Therefore we were interested
in determining whether E6 could modulate the levels to which S5a
is ubiquitinated in vivo. To do this, 293 cells were transfected with
HPV-16 E6 or HPV-18 E6, plus S5a and HA-tagged ubiquitin
expression plasmids. After 24 h proteasome inhibitors were added
and the cells were incubated for a further 3 h. Ubiquitinated
proteins were then immunoprecipitated from the cell extracts
using anti-HA antibodies, and the pattern of S5a expression was
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Inputs
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Fig. 2. High- and low-risk HPV E6 proteins recognise proteasome subunits with
similar efﬁciency. The indicated proteasome subunits were expressed and puriﬁed
as GST fusion proteins and incubated with in vitro translated and radiolabelled
HPV-11, HPV-16 and HPV-18 E6 proteins in WGE. After extensive washing the
bound proteins were detected following SDS-PAGE and autoradiography. The upper
panel shows the autoradiograph of bound E6. The GST inputs are also shown as a
Coomassie stained gel, with arrows indicating the full-length GST proteins. The
bottom panel shows 20% of the input E6 proteins used in the pull down assays and
the numbers represent the mean percentage of input protein bound from at least
3 independent assays.
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Fig. 3. HPV-18 E6 interacts with the S5a proteasome subunit in an E6AP dependent
manner. Panel A. The indicated proteasome subunits were expressed as GST fusion
proteins and puriﬁed. These were then incubated with in vitro translated and
radiolabelled HPV-18 E6 in rabbit reticulocyte lysate. After extensive washing the bound
protein was detected by SDS-PAGE and autoradiography. The upper panel shows the
autoradiograph of bound E6 together with 20% of the E6 input. The bottom panel shows
the Coomassie stain of the gel showing the levels of GST inputs used in the pull down
assays. Panel B. 293 control TR2 scrambled shRNA (i) and 293 shRNA E6AP,
(ii) cells were transfected with HA-tagged HPV-18 E6 expression plasmid and after
24 h cells, were harvested and extracts incubated with the indicated puriﬁed GST fusion
proteins. After extensive washing, bound E6 was detected byWestern blotting using the
anti-HA antibody and is compared with the amount of E6 present in 10% of the
input. The lower panels in each case show the Ponceau stains of the nitrocellulose
membranes showing the levels of GST proteins used in the pull downs with the arrows
indicating the position of the GST and GST fusion proteins. The lower panel (iii) shows
the Western blot of E6AP expression levels in the control 293 cells transfected with
scrambled shRNA (TR2) and cells transfected with shRNA E6AP. Also shown is the
α-actinin loading control.
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analysed by Western blotting with anti-S5a antibody. The results
obtained are shown in Fig. 5A. In the absence of E6 there are
signiﬁcant amounts of ubiquitin-conjugated S5a protein, which
increase following proteasome inhibition. In the presence of HPV-
16 E6, the levels of ubiquitinated S5a are slightly higher and these
increase dramatically upon proteasome inhibition. However in
the presence of HPV-18 E6 there is minimal change in the level
of ubiquitinated S5a. These results reﬂect the patterns of mod-
iﬁcation seen in vitro, and demonstrate that HPV-16 E6 can
modulate the levels of S5a ubiquitination in vivo.
We then wanted to determine whether E6AP might also
modulate the levels to which S5a is ubiquitinated. To do this,
293 cells were transfected with S5a and HA-tagged ubiquitin
together with combinations of HPV-16 E6 or E6AP. The pattern
of S5a expression was then ascertained following anti-HA immu-
noprecipitation and Western blotting. The results in Fig. 5B again
demonstrate that HPV-16 induces a strong increase in the levels of
S5a ubiquitination, and this is even more apparent when E6AP is
overexpressed, demonstrating that it can also directly affect the
levels of S5a ubiquitination in vivo. When both E6 and E6AP are co-
expressed there is a marked reduction in total S5a levels, and
indications of higher molecular weight forms of ubiquitinated
protein. Interestingly, these ubiquitinated forms of S5a appear to
be extremely susceptible to rescue by MG132 treatment. These
results suggest that E6-induced ubiquitination of S5a renders it
susceptible to degradation at the proteasome, whereas E6AP-
induced ubiquitination does not. When E6 and E6AP are co-
expressed, then S5a is ubiquitinated, but appears to be directed
more efﬁciently for degradation. These results suggest that both E6
and E6AP can modulate the levels of S5a ubiquitination, but that
the consequences of such ubiquitination are somewhat different.
We were also interested in determining whether E6AP was in
complex with S5a in the immunoprecipitations. To do this, the
Western blots were re-probed for E6AP and the results are also
shown in Fig. 5B. As can be seen, a small amount of E6AP appears
to be co-precipitated with ubiquitin and S5a, and this is in
agreement with previous studies (Uchiki et al., 2009). The amount
of E6AP co-precipitated also increases signiﬁcantly in the presence
of HPV-16 E6 when MG132 is also present, and interestingly, the
amount is directly proportional to the amount of ubiquitinated S5a
that is immunoprecipitated. This suggests that the E6AP in com-
plex with ubiquitinated S5a is also subject to proteasome
mediated degradation.
Discussion
The ability of the HPV E6 oncoproteins to direct the degrada-
tion of their substrates for proteasome-mediated degradation
appears to be a central facet of their ability to support the virus
life cycle, and also to ultimately induce cancer (Doorbar et al.,
2012). Much of this activity is linked to their capacity to act as a
bridge between the E6AP ubiquitin ligase and the respective target
proteins, thereby resulting in polyubiquitination of the substrate
and its subsequent degradation at the 26S proteasome (Scheffner
et al., 1993). We now show that E6 also has the potential to
1hr0 1hr 3hr 30’ 3hr 30’ 1hr 3hr
S5a+16 E6 S5a+18 E6S5a+WPL
S5a
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p53
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Fig. 4. HPV-16 E6 induces S5a polyubiquitination in vitro. Panel A. HPV-16 E6, HPV-18 E6 and the S5a proteasome subunit were in vitro translated and radiolabelled in RRL.
These were then mixed as indicated and incubated at 30 1C for the 30 min, 1 h and 3 h. Remaining protein was then visualised by SDS-PAGE and autoradiography. Note the
appearance of slower migrating forms of S5a in the presence of HPV-16 E6. Panel B. HPV-16 E6 and the S5a proteasome subunit were in vitro translated as in Panel A, and
mixed and incubated for the indicated times. Note the appearance of slower migrating forms of S5a 15–30 min post incubation with E6 as indicated by the arrows and the
progressive loss of the higher molecular weight slower migrating forms over time. The left hand panel shows a parallel assay performed with p53 where E6 induces rapid
degradation of the protein after as little as 5 mins incubation.
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interact directly with a number of speciﬁc proteasome subunits.
Furthermore, these studies highlight the S5a subunit as a particu-
larly intriguing novel target of the E6 oncoprotein. It is bound
strongly by E6 in an E6AP-dependent manner and, in addition,
appears to be subjected to increased levels of ubiquitination in the
presence of E6, both in vitro and in vivo.
A number of proteomic studies have demonstrated that the
HPV E6 oncoproteins interact closely with the ubiquitin protea-
some machinery, with many different proteasome subunits being
identiﬁed in these analyses (Tomaić et al., 2011; Rozenblatt-Rosen
et al., 2012). These studies used immunoprecipitations coupled
with mass spectrometry to identify E6 protein partners, and
indicated a close proximity of E6 to the proteasome machinery.
However these studies did not verify these associations with the
proteasome, nor did they analyse the potential of individual
proteasome subunits to interact with E6. To address these issues
we performed an extensive series of in vitro interaction assays
between E6 and a panel of isolated proteasome subunits. We have
identiﬁed multiple subunits as potentially direct interacting part-
ners of all the HPV E6 oncoproteins analysed, with the S4 and S8
being consistently the strongest bound subunits in these in vitro
assays. Weak interactions were obtained with S2, S6a, S6b and S7,
but no interaction was observed with S5a or S9 in vitro. Obviously
we cannot exclude the possibility of indirect associations with
some of these subunits, possibly via a primary interacting target
such as S4 or S8. In addition, in the majority of cases these assays
were performed in wheat germ expression systems, thereby
excluding the E6AP ubiquitin ligase from having a role in these
interactions. Finally, differences in the strengths of association
between E6 and the different subunits and the fact that efﬁcient
interactions were obtained regardless of the manner in which the
E6 and proteasome subunits are expressed (GSTs or in vitro
translated) also tends to preclude a major involvement of indirect
protein interactions in most cases. Interestingly, the full length
HPV-18 E6 recognised a proteasome subunit proﬁle very similar to
that seen with the alternatively spliced HPV-18 E6n protein. This
-- + -+ +
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Fig. 5. HPV-16 E6 induces S5a polyubiquitination in vivo. Panel A. 293 cells were transfected with S5a, S5a plus HA.ubiquitin (HA-Ub) expressing plasmid together with HPV-
16 or HPV-18 E6 expression plasmids as indicated. After 24 h the cells were incubated with MG132 for 3 h (þ), as indicated, and then extracted and immunoprecipitated
using anti-HA antibody conjugated agarose beads. Ubiquitin bound S5a was then detected by Western blotting with anti S5a antibody. The lower panel shows the input
levels of S5a protein used in the immunoprecipitations. Panel B. 293 cells were transfected with S5a plus HA-Ub expression plasmids together with HPV-16 E6 and E6AP as
indicated. After 24 h the cells were incubated with MG132 for 3 h (þ) and ubiquitin bound S5a was detected by Western blotting with anti-S5a antibody. The co-
immunoprecipitating E6AP was detected by Western blotting using anti E6AP antibody. The lower panels show the input levels of S5a and E6AP used in the
immunoprecipitations.
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suggests that the capacity of E6 to associate with these protea-
some subunits is mediated by amino acid residues that reside
largely within the N-terminal region of the E6 protein. In addition,
both HPV-11 and HPV-16 E6 were also found capable of interacting
with the isolated proteasome components, although HPV-16 E6
bound these subunits consistently more strongly than either the
HPV-11 or HPV-18 E6 proteins. These results therefore conﬁrm
speciﬁc proteasome subunits as bona ﬁde interacting partners of
E6. It is also intriguing to note that the apparent strength of
association with the proteasome subunits does reﬂect the degree
of association with cancer development, suggesting that this series
of interactions may be directly relevant to the ability of E6 to
contribute towards tumour development.
As noted above the S5a subunit was absent in the in vitro pull
down assays when E6AP was not present. This was surprising,
since S5a had been detected previously in a number of the
proteomic analyses, and the protein appears to play a central role
in the ubiquitin proteasome pathway. However, when these
interaction assays were performed in the presence of E6AP,
a robust interaction was obtained with HPV-18 E6. This suggested
that S5a ﬁtted into the class of E6 substrates that are part of the
E6-E6AP complex, raising the possibility that the S5a subunit
might be subject to proteolytic degradation by the E6 oncoprotein.
Surprisingly our in vitro assays indicate only weak levels of
proteasome-mediated degradation by E6, but a marked increase
in the presence of slower migrating higher molecular weight
forms of the protein, indicative of increased rates of ubiquitination.
This ability of E6 to stimulate ubiqutination of S5a correlates
directly with its ability to interact with E6AP, with HPV-16 E6
being much more efﬁcient at binding S5a and interacting with
E6AP (Scheffner et al., 1993) when compared with HPV-18 E6.
Previous studies had indeed shown that the E6AP ubiquitin ligase
could interact with the S5a subunit (Uchiki et al., 2009; Martinez-
Noel et al., 2012), and our studies demonstrate that overexpressed
E6AP can signiﬁcantly increase the levels of S5a ubiquitination
in vivo, but without signiﬁcantly affecting its susceptibility to
proteasome mediated degradation. In contrast, HPV-16 E6 also
increases the levels of S5a ubiquitination, which appears to be
dependent upon the presence of E6AP. However, in this case these
ubiquitinated forms of S5a appear signiﬁcantly more susceptible to
proteasome turnover. When E6 and E6AP are both co-expressed
with S5a, then the ubiquitinated S5a appears highly susceptible to
proteasome mediated degradation. These results indicate that
whilst E6 has no major effect on the total levels of S5a protein
expression, the E6-induced ubiquitinated S5a is more susceptible
to proteasome-mediated degradation than the E6AP-induced ubi-
quitinated forms of S5a. This suggests that E6 redirects either the
patterns or the levels of E6AP induced ubiquitination of the S5a
subunit. Whether this is directly related to the ability of E6 to
redirect many of its protein partners to the proteasome remains to
be determined. However it is possible that this activity may have a
broader consequence for the overall functioning of the protea-
some, possibly by increasing its overall activity. In addition, whilst
we can detect E6 interaction and induced polybiqutination of S5a,
it is important to remember that considerable amounts of S5a are
not directly associated with the proteasome, and currently we do
not know which pools of S5a are being directly targeted by E6.
Therefore, whether these non-proteasome bound forms of S5a are
also relevant for E6 function is an open question and requires
further investigation.
Taken together, these results demonstrate a complex interplay
between the HPV E6 oncoproteins and the ubiquitin proteasome
pathway. Further studies are now required to elucidate the biological
relevance of the ability of E6 to increase ubiquitination of the S5a
proteasome subunit, and to determine how this might affect the
overall functioning of the proteasome pathway within the cell.
Materials and methods
Cells and transfections
HEK293 cells were grown in Dulbecco's modiﬁed Eagle's
medium (DMEM) supplemented with 10% foetal calf serum
(FCS). Transfections were done using calcium phosphate precipita-
tions (Matlashewski et al., 1987). HEK293 cells stably ablated for
E6AP expression were generated by transfecting cells with expres-
sion vectors containing targeting sequences that were scrambled
(TR2) or directed against human E6AP (shRNA E6AP) that were
purchased from OriGene. Cells were placed under selection for
3 weeks and after this time clones were isolated and analysed for
E6AP expression levels by western blotting. One such clone stably
ablated for E6AP was used in the study.
Plasmids
The HPV-11 E6, HPV-16 E6, HPV-18 E6 and p53 expression
plasmids have been described previously (Gardiol et al., 1999; Pim
et al., 1994; Pim et al., 1997; Thomas and Banks, 1999), as have the
different proteasome subunit expression plasmids (Jin et al., 2008).
The GST-fusion proteins HPV-18 E6 and HPV-18 E6n have been
described previously (Pim et al., 1997; Thomas et al., 1996).
Antibodies
The following antibodies were used: anti-HA monoclonal anti-
body 12CA5 (Roche), anti-S5a polyclonal antibody (Proteintech) and
anti-E6AP monoclonal antibody (BD, Transduction Laboratories).
Fusion protein puriﬁcation and in vitro binding assays
GST-tagged fusion proteins were expressed and puriﬁed as
described previously (Thomas et al., 1996). Proteins were trans-
lated in vitro using a Promega TNT kit and radiolabeled with [35S]
cysteine or [35S]methionine (Perkin Elmer). Equal amounts of
in vitro translated proteins were added to GST fusion proteins
bound to glutathione agarose (Sigma) and incubated for 1 h at
4 1C. After extensive washing with phosphate-buffered saline
(PBS) containing 0.25% NP-40, the bound proteins were analysed
by SDS-PAGE and autoradiography.
GST pulldowns using cellular extracts were performed by
incubating GST fusion proteins immobilised on glutathione agar-
ose with cells extracted in E1A buffer (50 mM HEPES, pH 7.0,
250 mM NaCl, 0.1% NP-40, plus protease inhibitor cocktail set I
[Calbiochem]) for 1 h at 4 1C on a rotating wheel. After extensive
washing, the bound proteins were detected using SDS-PAGE and
Western blotting. Protein detections were done as described
previously (Tomaić et al., 2009).
Immunoprecipitations and western blotting
Cells were transfected with the indicated expression plasmids
and after 24 h were incubated in the presence of 50 mM MG132 or
DMSO control for 3 h as indicated. The cells were then harvested
and extracted with E1a extraction buffer (50 mM HEPES, pH 7.0,
250 mM NaCl, 0.1% NP-40). Cell extracts were then incubated with
anti-HA conjugated agarose beads (Sigma) for 2 h on a rotating
wheel at 4 1C. The beads were then extensively washed, and
immunoprecipitates were analysed for S5a using anti S5a antibody
by SDS-PAGE and Western blotting. Protein detections were done
as described previously (Tomaić et al., 2009).
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In vitro degradation assays
Proteins were transcribed and translated in vitro in rabbit
reticulocyte lysate or wheat germ extracts using the Promega
TNT system according to the manufacture's instruction. The HPV-
18 E6 and HPV-16 E6 were radiolabelled with [35S]-cysteine
(Perkin Elmer) while S5a and p53 were radiolabelled with [35S]-
methionine (Perkin Elmer). Degradation assays were performed as
previously described (Thomas et al., 2001). Brieﬂy, radiolabelled
proteins were mixed and incubated for the indicated times at
30 1C. Volumes were adjusted using water-primed lysate. The
remaining S5a or p53 proteins were analysed by SDS-PAGE and
autoradiography.
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